Siga Technologies Inc (SIGA) 1.95 $SIGA
SIGA Technologies: Uncovering Hidden Value In Bankruptcy
Understanding Businesses - at Seeking Alpha - Wed Feb 11, 4:00AM CST
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Siga appeals court ruling
Seeking Alpha - at Seeking Alpha - Sat Jan 17, 11:34AM CST
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery
Business Wire - Fri Jan 16, 3:10PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that it has filed a notice of appeal from the judgment of the Delaware Court of Chancery awarding PharmAthene, Inc. expectation damages.
SIGA: 1.95 (-0.01)
PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery
PR Newswire - Thu Jan 15, 3:08PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the Company's litigation against SIGA Technologies, Inc. The Court's judgment against SIGA totaled $194,649,041.74, including $113,116,985.00 in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, and $81,532,056.74 in pre-judgment interest and attorneys' and expert witness fees. In addition, SIGA will be required to pay post-judgment interest of $30,663.89 per day, beginning today.
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
Delaware Court Decision Regarding SIGA Technologies, Inc.
Business Wire - Wed Jan 07, 4:29PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that on January 7, 2015, the Delaware Court of Chancery, acting on remand from the Delaware Supreme Court, issued a letter opinion in the litigation begun by PharmAthene, Inc. in 2006.
SIGA: 1.95 (-0.01)
Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014
PRWeb - Fri Nov 28, 7:30PM CST
The report "Poxvirus Infections Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.reportsnreports.com/reports/318830...-2014.html .
SIGA: 1.95 (-0.01)
PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment
PR Newswire - Wed Oct 08, 11:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially lifted the stay of PharmAthene's litigation against SIGA Technologies, Inc., in the Delaware Court of Chancery. The order allows the Chancery Court to issue a final judgment and the parties to pursue appeals thereof. Enforcement of any judgment, once entered will remain subject to the Bankruptcy Court stay.
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Receives Bankruptcy Court Approval for First-Day Motions in Connection with Chapter 11 Case
Business Wire - Wed Sep 17, 6:46PM CDT
SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it has received Bankruptcy Court approval of "first-day" motions that it filed on September 16, 2014, the date on which it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York. The approval of these "first-day" motions by the Bankruptcy Court will assure that SIGA's operations will continue seamlessly in chapter 11 and that it will be business as usual.
SIGA: 1.95 (-0.01)
Siga Technologies files for Ch 11 reorganization
AP - Tue Sep 16, 7:26AM CDT
NEW YORK (AP) — Drug developer Siga Technologies has filed a petition for Chapter 11 reorganization in U.S. Bankruptcy Court as it appeals a court ruling on its smallpox drug Tecovirimat.
SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Files for Chapter 11 Reorganization
Business Wire - Tue Sep 16, 5:48AM CDT
SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it has filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York.
SIGA: 1.95 (-0.01)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Sep 12, 8:03AM CDT
These stocks under $10 are within range of triggering breakout trades.
MDWD: 7.22 (+0.17), SIGA: 1.95 (-0.01), SNMX: 5.92 (+0.26), XOMA: 3.41 (-0.01)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
Why SIGA Technologies (SIGA) Stock Plunged to a One-Year Low Today
at The Street - Mon Aug 11, 2:37PM CDT
SIGA Technologies (SIGA) plunged to a 52-week low of $1.62 on Monday after a Delaware court ruled the company must pay a lump sum in damages to PharmAthene (PIP).
SIGA: 1.95 (-0.01)
Delaware Court of Chancery Issues Ruling on Remand in PharmAthene Litigation
GlobeNewswire - Sun Aug 10, 7:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that, on August 8, 2014, the Delaware Court of Chancery issued its decision on remand in the litigation begun by PharmAthene, Inc. in 2006. In his opinion, Vice Chancellor Parsons determined, among other things, that PharmAthene is entitled to a lump sum damage award in a still unspecified amount, with interest and fees, based on U. S. Government purchases of SIGA's smallpox drug supposedly anticipated in 2006. The total award is likely to be substantial, but it will not be established until after the Court considers calculations to be provided by a designated expert. In coming to its conclusion, the Court reversed its own prior ruling that expectation damages were not recoverable because they were too speculative. The Court's most recent decision now holds that expert testimony from the original trial, which it had previously found to be too speculative, supports an award of expectation damages. William J. Haynes II, SIGA's General Counsel, commented, "While we are not surprised that the Court left undisturbed SIGA's ownership and control of our smallpox drug, we respectfully disagree with the Chancery Court's decision on damages. We believe that aspect of this decision is not supported by the record or the law, and we expect to appeal it to the Supreme Court of Delaware."
SIGA: 1.95 (-0.01)
SIGA to Host Quarterly Business Update Call on August 4, 2014
GlobeNewswire - Thu Jul 31, 3:43PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 4, 2014.
SIGA: 1.95 (-0.01)
Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
TTPH: 35.18 (-0.73), SYN: 2.13 (+0.18), IMUC: 0.54 (-0.03), SIGA: 1.95 (-0.01), RTGN: 4.20 (+0.08)
SIGA Technologies Reports Financial Results for the Second Quarter 2014
GlobeNewswire - Thu Jul 31, 7:15AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the three and six months ended June 30, 2014.
SIGA: 1.95 (-0.01)
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
SIGA Technologies: Uncovering Hidden Value In Bankruptcy
Understanding Businesses - at Seeking Alpha - Wed Feb 11, 4:00AM CST
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 34.09 (+0.10), JNJ: 99.62 (+1.18), UTHR: 151.11 (+3.59), MRK: 58.81 (-0.07), NNVC: 2.97 (-0.05), GSK: 47.94 (+1.99), SIGA: 1.95 (-0.01)
Siga appeals court ruling
Seeking Alpha - at Seeking Alpha - Sat Jan 17, 11:34AM CST
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery
Business Wire - Fri Jan 16, 3:10PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that it has filed a notice of appeal from the judgment of the Delaware Court of Chancery awarding PharmAthene, Inc. expectation damages.
SIGA: 1.95 (-0.01)
PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery
PR Newswire - Thu Jan 15, 3:08PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the Company's litigation against SIGA Technologies, Inc. The Court's judgment against SIGA totaled $194,649,041.74, including $113,116,985.00 in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, and $81,532,056.74 in pre-judgment interest and attorneys' and expert witness fees. In addition, SIGA will be required to pay post-judgment interest of $30,663.89 per day, beginning today.
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
Delaware Court Decision Regarding SIGA Technologies, Inc.
Business Wire - Wed Jan 07, 4:29PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that on January 7, 2015, the Delaware Court of Chancery, acting on remand from the Delaware Supreme Court, issued a letter opinion in the litigation begun by PharmAthene, Inc. in 2006.
SIGA: 1.95 (-0.01)
Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014
PRWeb - Fri Nov 28, 7:30PM CST
The report "Poxvirus Infections Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.reportsnreports.com/reports/318830...-2014.html .
SIGA: 1.95 (-0.01)
PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment
PR Newswire - Wed Oct 08, 11:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially lifted the stay of PharmAthene's litigation against SIGA Technologies, Inc., in the Delaware Court of Chancery. The order allows the Chancery Court to issue a final judgment and the parties to pursue appeals thereof. Enforcement of any judgment, once entered will remain subject to the Bankruptcy Court stay.
PIP: 1.71 (unch), SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Receives Bankruptcy Court Approval for First-Day Motions in Connection with Chapter 11 Case
Business Wire - Wed Sep 17, 6:46PM CDT
SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it has received Bankruptcy Court approval of "first-day" motions that it filed on September 16, 2014, the date on which it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York. The approval of these "first-day" motions by the Bankruptcy Court will assure that SIGA's operations will continue seamlessly in chapter 11 and that it will be business as usual.
SIGA: 1.95 (-0.01)
Siga Technologies files for Ch 11 reorganization
AP - Tue Sep 16, 7:26AM CDT
NEW YORK (AP) — Drug developer Siga Technologies has filed a petition for Chapter 11 reorganization in U.S. Bankruptcy Court as it appeals a court ruling on its smallpox drug Tecovirimat.
SIGA: 1.95 (-0.01)
SIGA Technologies, Inc. Files for Chapter 11 Reorganization
Business Wire - Tue Sep 16, 5:48AM CDT
SIGA Technologies, Inc. (NASDAQ:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced today that it has filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York.
SIGA: 1.95 (-0.01)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Sep 12, 8:03AM CDT
These stocks under $10 are within range of triggering breakout trades.
MDWD: 7.22 (+0.17), SIGA: 1.95 (-0.01), SNMX: 5.92 (+0.26), XOMA: 3.41 (-0.01)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
Why SIGA Technologies (SIGA) Stock Plunged to a One-Year Low Today
at The Street - Mon Aug 11, 2:37PM CDT
SIGA Technologies (SIGA) plunged to a 52-week low of $1.62 on Monday after a Delaware court ruled the company must pay a lump sum in damages to PharmAthene (PIP).
SIGA: 1.95 (-0.01)
Delaware Court of Chancery Issues Ruling on Remand in PharmAthene Litigation
GlobeNewswire - Sun Aug 10, 7:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that, on August 8, 2014, the Delaware Court of Chancery issued its decision on remand in the litigation begun by PharmAthene, Inc. in 2006. In his opinion, Vice Chancellor Parsons determined, among other things, that PharmAthene is entitled to a lump sum damage award in a still unspecified amount, with interest and fees, based on U. S. Government purchases of SIGA's smallpox drug supposedly anticipated in 2006. The total award is likely to be substantial, but it will not be established until after the Court considers calculations to be provided by a designated expert. In coming to its conclusion, the Court reversed its own prior ruling that expectation damages were not recoverable because they were too speculative. The Court's most recent decision now holds that expert testimony from the original trial, which it had previously found to be too speculative, supports an award of expectation damages. William J. Haynes II, SIGA's General Counsel, commented, "While we are not surprised that the Court left undisturbed SIGA's ownership and control of our smallpox drug, we respectfully disagree with the Chancery Court's decision on damages. We believe that aspect of this decision is not supported by the record or the law, and we expect to appeal it to the Supreme Court of Delaware."
SIGA: 1.95 (-0.01)
SIGA to Host Quarterly Business Update Call on August 4, 2014
GlobeNewswire - Thu Jul 31, 3:43PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 4, 2014.
SIGA: 1.95 (-0.01)
Biotechnology Sector in Focus
ACCESSWIRE - Thu Jul 31, 8:01AM CDT
Deerfield Beach, FL / ACCESSWIRE / July 31, 2014 / One of the major concerns for big pharma is patent expirations. Patent expirations will result in a loss of $34 billion in revenue at big pharma companies this year. This was after pharma companies lost $55 billion and $28 billion in revenue in 2012 and 2013, respectively. In 2015, products worth $66 billion will see their patents expire.
TTPH: 35.18 (-0.73), SYN: 2.13 (+0.18), IMUC: 0.54 (-0.03), SIGA: 1.95 (-0.01), RTGN: 4.20 (+0.08)
SIGA Technologies Reports Financial Results for the Second Quarter 2014
GlobeNewswire - Thu Jul 31, 7:15AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the three and six months ended June 30, 2014.
SIGA: 1.95 (-0.01)
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
MGNX: 34.09 (+0.10), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), SIGA: 1.95 (-0.01)
